Biologics – Page 4 – Pharma.Tips

Biologic host cell protein (HCP) OOS after upstream media/raw material change: patient safety impact assessment and batch disposition governance

The detection of OOS HCP results can present itself through various signals during routine quality control testing of final outputs. Common symptoms include:Click to read the full article.

Biologic filter integrity failure during CPV trending review: single-use systems risk controls, leachables review, and supplier oversight actions

Symptoms of a biologic filter integrity failure often manifest through unexpected deviations in batch quality attributes. The initial observations might include:Click to read the full article.

Biologic comparability failure after process change during FDA/EMA inspection readiness: CAPA package with CQA/CPP risk assessment and effectiveness verification

Biologic comparability failures can present several observable symptoms either during routine testing or pre-inspection evaluations. Identification of these signals is crucial for timely investigation:Click to read the full article.

Biologic stability failure (real-time/accelerated) during deviation investigation board review: CAPA package with CQA/CPP risk assessment and effectiveness verification

While conducting routine assessments, several key signals may indicate a potential biologic stability failure. Recognizing these symptoms early can help minimize risk and allow for an efficient investigation process:Click to…

Biologic potency drift during commercial manufacturing campaign: investigation strategy aligned to FDA/EMA expectations and comparability principles

Symptoms of biologic potency drift can manifest in various forms, signalling potential issues that warrant immediate investigation. Common signals include:Click to read the full article.

Biologic container closure integrity failure after equipment qualification update: viral safety and contamination response plan with inspection-ready evidence

Identifying initial signals of container closure integrity failure is crucial for prompt action. Operational departments should be vigilant for indicators such as:Click to read the full article.

Biologic stability failure (real-time/accelerated) during tech transfer to a CMO: viral safety and contamination response plan with inspection-ready evidence

The identification of symptoms related to biologic stability failures should begin with careful observation both in the laboratory and during production runs. Some common signals include:Click to read the full…

Biologic comparability failure after process change after filling line intervention: how to justify rework/reprocessing vs rejection for biologic lots

Identifying symptoms and signals is the first step in investigating biologic comparability failures. These indicators can manifest in several forms:Click to read the full article.

Biologic viral clearance validation gap after equipment qualification update: patient safety impact assessment and batch disposition governance

The initial detection of a biologic viral clearance validation gap often emerges through various symptoms reported either on the manufacturing floor or within laboratory environments. Common signals include:Click to read…

Biologic container closure integrity failure during CPV trending review: patient safety impact assessment and batch disposition governance

Spotting the early signs of container closure integrity failures is crucial. Symptoms can occur at various stages throughout the manufacturing process. Here are some common signals:Click to read the full…

Biologic stability failure (real-time/accelerated) during PPQ / process validation: single-use systems risk controls, leachables review, and supplier oversight actions

The first step in an investigation of biologic stability failures during process validation is identifying the symptoms or signals. These may present as:Click to read the full article.